9
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Growth Inhibition of Plasmodium Falciparum Involving Carbon Centered Iron-Chelate Radical (L., X-)-Fe(III) Based on Pyridoxal-Betaine. A Novel Type of Antimalarials Active Against Chloroquine-Resistant Parasites

, , , &
Pages 1-10 | Received 27 Mar 1990, Published online: 07 Jul 2009
 

Abstract

Malaria parasites have been shown to be more susceptible to oxidative stress than their host erythro- cytes. In the present work, a chloroquine resistant malaria parasite, Plasmodium falciparum (FCR-3) was found to be susceptible in vitro to a pyridoxal based iron chelator — (l-[N-ethoxycarbonylmethyl- pyridoxlidenium]-2-[2′-pyridyl] hydrazine bromide — (code named L2–9). 2h exposure to 20μM L2–9 was sufficient to irreversibly inhibit parasite growth. Desferrioxamine blocked the drug effect, indicating the requirement for iron. Oxygen however, was not essential. Spectrophotometric analysis showed that under anoxic conditions, L2–9-Fe(II) chelate undergoes an intramolecular redox reaction which presumably involves a one electron transfer and is expected to result in the formation of free radical. Spin trapping coupled to electron spin resonance (ESR) studies of L2–9-iron chelate showed that L2–9-Fe(II) produced free radicals both in the presence and absence of cells, while L2–9-Fe(III) produced free radicals only in the presence of actively metabolising cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.